{"name":"Lantheus Medical Imaging","slug":"lantheus-medical-imaging","ticker":"","exchange":"","domain":"lantheusmedicalimaging.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"DEFINITY","genericName":"DEFINITY","slug":"definity","indication":"Other","status":"marketed"},{"name":"Sestamibi","genericName":"Sestamibi","slug":"sestamibi","indication":"Myocardial Imaging","status":"marketed"},{"name":"Ablavar","genericName":"Ablavar","slug":"ablavar","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Technetium Tc99m Sestamibi","genericName":"Technetium Tc99m Sestamibi","slug":"technetium-tc99m-sestamibi","indication":"Myocardial perfusion imaging to assess coronary artery disease and ischemia","status":"marketed"}]}],"pipeline":[{"name":"DEFINITY","genericName":"DEFINITY","slug":"definity","phase":"marketed","mechanism":"Definity works by being taken up by cells in the body, where it is metabolized and eventually eliminated.","indications":[],"catalyst":""},{"name":"Sestamibi","genericName":"Sestamibi","slug":"sestamibi","phase":"marketed","mechanism":"Small molecule","indications":["Myocardial Imaging","Breast Imaging"],"catalyst":""},{"name":"Ablavar","genericName":"Ablavar","slug":"ablavar","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Technetium Tc99m Sestamibi","genericName":"Technetium Tc99m Sestamibi","slug":"technetium-tc99m-sestamibi","phase":"marketed","mechanism":"Technetium Tc-99m sestamibi is a radiopharmaceutical that accumulates in mitochondria of viable myocardial cells, allowing visualization of myocardial perfusion and viability via nuclear imaging.","indications":["Myocardial perfusion imaging to assess coronary artery disease and ischemia","Evaluation of myocardial viability in patients with coronary artery disease","Risk stratification in patients with known or suspected coronary artery disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQOXZSenYxVnV4T2hLNE9KRmoxRzRTakVLaTh2UlZsSTVLTmhrVDFGaGFrdmhDQVRSZDFaZlEtdXVDYXdtbE9kS3dCXzdDY1JHZnZvbW9tbzlMbnRnaWVMUGl1QU90RnJJVTFpd2F4THdwT3FCS0t5YWdNWWg3TUE4N2FWM3ZHTUdZelFLRTdoY01MMGhNbXNZWUNSeDhsSmJ3SDlGRkloaER0SlVRcFF0MU14TU5JMEY5Rnh6bkI5RzJJcWRZZzRnSkpFVWx5NTkwSWc?oc=5","date":"2026-03-06","type":"regulatory","source":"Reuters","summary":"US FDA approves Lantheus' new prostate cancer imaging formulation - Reuters","headline":"US FDA approves Lantheus' new prostate cancer imaging formulation","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNZkhJNzVKRzN2VEpXOU16X1RmSXZXYzhHOWNoWm14bFpZemZJUFBudzdVaUQtZ1F0YWQ0ZHE3YzV4SFVyaEtDazEwaEowM21sMnAzTnhlM09WRWdFVTJBdUpaelBvTmdmanRQaDJucUtOUW9CQlQzclVTOEN2cmlJajlkYVNNSU9DaDg3MkRNUmdQQk90RFkxS054cmxiWEk5Skh0NldaUDdndENTeVpfdDhsS1M0cjRMbDloZ2N6SjZDSkk?oc=5","date":"2026-01-29","type":"pipeline","source":"AD HOC NEWS","summary":"The Truth About Lantheus Holdings Inc: Why Wall Street Is Quietly Losing It Over LNTH - AD HOC NEWS","headline":"The Truth About Lantheus Holdings Inc: Why Wall Street Is Quietly Losing It Over LNTH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPYkNDVXdCS3Z5LU5YTnhUMkREWnZ6M2k2eFJUSW1wU0d2VnhJTnhPMzkxeVJSMExPeEYySHBDdGpTVjhsRWVzZjh6SVBHdGdFS281T09pNUlxaE12aEx2dXFyZ0hCSUNhZXBEbTB3UXZBblBQNnF0ZEROUU1OZUJCR2xrNUZST0ozZWR4WVYzWTd3NkFmQXlQZ213UlNRSVlHMVVFNzdwVWd1WlRRZUNOOHZob1J4R3l2SlIzbEQzYktiV1MxaUtLUGszWWQ1WlZDeUJLRA?oc=5","date":"2025-11-19","type":"pipeline","source":"Business Tech","summary":"South African company takes a hit after selling business to American pharmaceutical giant - Business Tech","headline":"South African company takes a hit after selling business to American pharmaceutical giant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQVnVxX1ZTdkhjZXJxU2c4d1psNHBEcmk4SlhIUWNDemlZT2cteWtDLUFnUjB1UFl6aTR5bi0wVGV4Nzh0ZHl1RzI2Qk1WRXN5b1JzQVV0S0QzRGNrenhZM243dXZtUXloT2tHYm5nT0pGVlRRQ0MxN2tyYmViR3NQdWVDQ3lILWN6TVBvTWszUFRJSllHZGl0UUM3MTBVTDd0Q2hfSHJYOGtkSU9yY0JLMy1kZUg4ZTJPaWN3b0Qtdw?oc=5","date":"2025-09-24","type":"pipeline","source":"Fierce Biotech","summary":"Lantheus hands GE HealthCare the rights to its blockbuster prostate cancer PET tracer in Japan - Fierce Biotech","headline":"Lantheus hands GE HealthCare the rights to its blockbuster prostate cancer PET tracer in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQMGlPaVhEd1hVVlRZOHFCVnJINV9XMVVQV1EyaHgzRVJjSXY2TFJ1eGlSd2FHQXkzblBHQmE0N0xPLVVvRjNkMDNCNlU0bUgtMEZxNGhIV2ZNak5KaVpGRW1FYThnblFyTEF6RHRZMVJkdk5KeUtTSVBrekRYSkVTdlZkQTdNeEw0UTN5aUdjbjZJd1pEZVdLd2RMeFdZangyRXJQWExMWmF0dWljaHBaVjJFN1lfZENWeVhtVzJmMldhZ1hQVVVkUDl0bVhlbmxJTGd1djRtOG5fSFlkSndhSA?oc=5","date":"2025-06-12","type":"pipeline","source":"radiologybusiness.com","summary":"Radiopharma firm Telix launches new prostate cancer imaging agent Gozellix in US - radiologybusiness.com","headline":"Radiopharma firm Telix launches new prostate cancer imaging agent Gozellix in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPUHI3bzRlNU9OYkpDa0c3X3dzMVRyZGYySHJIX3ZLLUVkNk9rMlhMRU5pVDBmRUJvMnRGdDNTdGhTQXZ5TGRyOGVBZ2REbnlYMF9yck56OU5HcmxYWjJicGxEc2sxczZZMVQ0SGRPMDJIWHItbDF4MV9Wbmo2a3hrNk9ha1RZekZvSm1EYU9n?oc=5","date":"2025-05-12","type":"deal","source":"The Pharma Letter","summary":"Shine Technologies to acquire Lantheus' SPECT division - The Pharma Letter","headline":"Shine Technologies to acquire Lantheus' SPECT division","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVkNPQ0lZLW1NbDVlcXlVNlNTSkpGbmFNRHZtRkNLbHdoSjFBcWVoSTctblBFR1NudUR2X04zbkxpY01VUkM5dXdLSEczWHJIOVZWSW1UODRLYmpWN2xuaEMzTGxnY1VuRXJqdVo1ZXEtY0wwdl9HRFA4QVdlVWYycEYxS0dSN25VUXh4b01VeDdSQkdKaHJRcFpEZ0dXTUU?oc=5","date":"2025-01-28","type":"deal","source":"Contract Pharma","summary":"Lantheus Holdings to Acquire Evergreen Theragnostics - Contract Pharma","headline":"Lantheus Holdings to Acquire Evergreen Theragnostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNY0lKTjZEZjVCSEFKNFZScFlNazlsc2VTOTN3am1UOGFCNlR0T0ttT1d0eFIyaUpoZm1LYUJ0dWhUOEpUQ211cEJBNl9wOGZFZ2VjZ3drYmNJNXZEYTNMR0E0T3ZiWEJlNmNPVVBsNGFBcFo4Q2ttRV9ZNHZ0MDhwQlg1a1l5RTF4QmlXcFBVX3F4c3hJcXhZcUNGUlRSdXBvOUhrMzh1dVVJQ0hUVkNTeUZBSQ?oc=5","date":"2025-01-28","type":"pipeline","source":"Fierce Pharma","summary":"Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen - Fierce Pharma","headline":"Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQd1BHcWhzMXRkaTZNR1lER0JfeTk2cGEtb1doSmR4MEJrM0llSkp3RGVqTUtfYjJJWGpaTER0R3FwVEhHSW1uQmhtSmdWY1BNc0RjMTBMNnM0MTNMTTllanBiVF9FTzdoQktRWDBGVldUTHA0Nm1PclY0ZkVEWFRNbmkwNG1VR2hpNXpEaGpR?oc=5","date":"2024-01-24","type":"pipeline","source":"Yahoo Finance","summary":"Canada Nuclear Medicine Market Analysis Report 2024-2030, Featuring Nordion, Lantheus Medical Imaging, Cardinal Health, Jubilant Life Sciences, Isologic Innovative Radiopharmaceuticals & Curium Pharma","headline":"Canada Nuclear Medicine Market Analysis Report 2024-2030, Featuring Nordion, Lantheus Medical Imaging, Cardinal Health, ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxOT2xydTJkZU15eE5MU1FnbEFOYVYwRGRHVEN3ZzRKTG11MDRwbkRQMTNaaW0yQXYzX0JLbWNUY1dMLXEyZUlvUmpOcW42cUpyRXg5RWlqOTZCN09URGJOb3JKcVotdUV1YmpiOXFBR1dLM1VBcWZMcVNLZ3Y3M2lrdmZOdWRoTmZYeWtWZHAyREU5NERZT0JnV0gxdUcwa1BBSFhEckdJUTdXM1ZqYi1SbHBPOVI3dnJpUE9Db2Fmb2JSVTdaTFBnOVJzbFdvTnBGVVVTTDllV1I1STcxRV95Z2Noc0NZeE40b1pmVFhETGhydFJsVF9mQWdYc0x6TkpHb1lEbHFnR2trcjNmT2JrY3NMSHpVWVBWUjlJTlBHZ29ZcE02ZEx0d0pSVUR2Z1FEQnk5SWtRa2tta3lteEl5SDFuX0ozUjlTUnh1ODlTTXhsQXdrVVE?oc=5","date":"2023-07-11","type":"trial","source":"prnewswire.com","summary":"Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging - prnewswire.com","headline":"Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evalua","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQRGctMGVkQnBxZ01lOVdkQnBPcDA2OWNBanhCcDV5al9oNndJbk53bmV0Y2NQZEpHMlUtSm15dHZfeDZ4QzdHSXctWmJ3bTQzTy1DN2pUV19GOFM3QjVHRU5xUjZSMlRuMTYxV0RRLXIwYlVqS0ZZNmNEMVF0VGRQemFYZmU?oc=5","date":"2023-02-07","type":"deal","source":"MassDevice","summary":"Lantheus acquires Cerveau and its imaging agent for Alzheimer’s - MassDevice","headline":"Lantheus acquires Cerveau and its imaging agent for Alzheimer’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5DS3JVeGU5NEt3eHpWM0ZjVlVzOVhJOUdKMHE1NG9xNS0yM01hOVI1UnRaTlU4Wm9XdWVzSmNERGpublcwQkw0SEZ6Wnd6NjU4dnNzUUpCS2FfUkNRcDdGVmVNNkU2cmhsU0J5VVhnNFlWYm13d05kUkdQMFY?oc=5","date":"2020-06-22","type":"deal","source":"drugdeliverybusiness.com","summary":"Lantheus, Progenics complete merger - drugdeliverybusiness.com","headline":"Lantheus, Progenics complete merger","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":3,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}